Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry.

Autor: Jatuworapruk K; Thammasat University, Thailand., Montgomery A; University of California San Francisco, San Francisco., Gianfrancesco M; University of California San Francisco, San Francisco., Conway R; St. James's Hospital and Trinity College Dublin, Ireland., Durcan L; Beaumont Hospital and Royal College of Surgeons of Ireland, Dublin., Graef ER; Boston University School of Medicine, Boston, Massachusetts., Jayatilleke A; Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania., Keen H; The University of Western Australia, Western Australia., Kilian A; Saint Louis University School of Medicine, St. Louis, Missouri., Young K; University of Arizona College of Medicine, Phoenix., Carmona L; Instituto de Salud Musculoesqueletica, Madrid, Spain., Cogo AK; Hospital Interzonal Luis Guemes, Haedo, and Hospital San Juan de Dios, Castelar, Buenos Aires, Argentina., Duarte-García A; Mayo Clinic, Rochester, Minnesota., Gossec L; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and AP-HP, Pitié-Salpêtrière Hospital, Paris, France., Hasseli R; University Hospital Giessen, Justus-Liebig-University Giessen, Germany., Hyrich KL; The University of Manchester and National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Langlois V; Groupe Hospitalier du Havre, Le Havre, France., Lawson-Tovey S; The University of Manchester, Manchester, UK., Malcata A; Serviço de reumatologia do Centro Hospitalar e Universitário de Coimbra, and Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal., Mateus EF; Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal., Schafer M; Epidemiology and Health Care Research, German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany., Scirè CA; Italian Society for Rheumatology, Milan, Italy., Sigurdardottir V; Uppsala University, Falun, Sweden., Sparks JA; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Strangfeld A; Epidemiology and Health Care Research, German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany., Xavier RM; Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil., Bhana S; Pfizer Inc., New York, New York., Gore-Massy M; Lupus Foundation of America, Washington, D.C., Hausmann J; Boston Children's Hospital, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Liew JW; Boston University School of Medicine, Boston, Massachusetts., Sirotich E; McMaster University, Hamilton, Ontario, Canada; Canadian Arthritis Patient Alliance., Sufka P; HealthPartners, St. Paul, Minnesota., Wallace Z; Massachusetts General Hospital and Harvard Medical School, Boston., Machado PM; University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; and Northwick Park Hospital, London North West University Healthcare NHS Trust London, UK., Yazdany J; University of California San Francisco, San Francisco., Grainger R; University of Otago Wellington, Wellington, New Zealand., Robinson PC; Royal Brisbane & Women's Hospital and University of Queensland School of Clinical Medicine, Herston, Queensland, Australia.
Jazyk: angličtina
Zdroj: ACR open rheumatology [ACR Open Rheumatol] 2022 Nov; Vol. 4 (11), pp. 948-953. Date of Electronic Publication: 2022 Aug 24.
DOI: 10.1002/acr2.11495
Abstrakt: Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.
Methods: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.
Results: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.
Conclusion: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
(© 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
Databáze: MEDLINE
Externí odkaz: